Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
24.61
-1.89 (-7.13%)
At close: Mar 9, 2026, 4:00 PM EDT
25.50
+0.89 (3.62%)
After-hours: Mar 9, 2026, 7:15 PM EDT
Evommune Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Net Income | -68.87 | -66.81 | -34.05 |
| Depreciation & Amortization | 1.39 | 1.29 | 1 |
| Loss (Gain) From Sale of Investments | -1.77 | -1.82 | -1.75 |
| Stock-Based Compensation | 5.86 | 1.72 | 1.48 |
| Other Operating Activities | -8.93 | - | - |
| Change in Accounts Payable | -0.84 | 6.51 | 0.13 |
| Change in Unearned Revenue | -3 | - | 3 |
| Change in Other Net Operating Assets | -0.28 | 0.92 | 0.22 |
| Operating Cash Flow | -76.44 | -58.2 | -29.97 |
| Capital Expenditures | -0.24 | -0.09 | -0.12 |
| Investment in Securities | -115.07 | -3.91 | -48.32 |
| Investing Cash Flow | -115.31 | -3.99 | -48.43 |
| Long-Term Debt Repaid | -0.53 | -0.42 | -0.23 |
| Net Debt Issued (Repaid) | -0.53 | -0.42 | -0.23 |
| Issuance of Common Stock | 157.29 | 0.01 | 0.01 |
| Repurchase of Common Stock | -1.22 | - | - |
| Financing Cash Flow | 220.76 | 49.42 | 63.75 |
| Net Cash Flow | 29.02 | -12.77 | -14.65 |
| Free Cash Flow | -76.68 | -58.28 | -30.09 |
| Free Cash Flow Margin | -589.82% | -832.61% | -601.76% |
| Free Cash Flow Per Share | -12.49 | -38.64 | -24.01 |
| Cash Interest Paid | 0.01 | 0.03 | 0.06 |
| Levered Free Cash Flow | -56.17 | -20.45 | - |
| Unlevered Free Cash Flow | -56.16 | -20.43 | - |
| Change in Working Capital | -4.12 | 7.42 | 3.34 |
Source: S&P Capital IQ. Standard template.
Financial Sources.